Vicky Collins
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 7
-
- Epilepsy research and treatment 3
- Journals
- The Lancet (6 papers)Nature (2 papers)Brain Communications (2 papers)The Lancet Neurology (1 paper)Lara D. Veeken (1 paper)
- Partner nations
- United KingdomVietnamNetherlands
In The Last Decade
Vicky Collins
13 papers receiving 1.8k citations
Vicky Collins's Hit Papers
Peers
Comparison fields: 5 of 86
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 35
- Neurology 67
- Statistics and Probability 47
Countries citing papers authored by Vicky Collins
This map shows the geographic impact of Vicky Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vicky Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vicky Collins more than expected).
Fields of papers citing papers by Vicky Collins
This network shows the impact of papers produced by Vicky Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vicky Collins. The network helps show where Vicky Collins may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 7 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 8 | 2021 | 79 | |
| 9 | 2023 | 60 | |
| 10 | 2023 | 9 | |
| 11 | 2022 | 8 | |
| 12 | 2022 | 6 | |
| 13 | 2023 | 6 |
About Vicky Collins
Vicky Collins is a scholar working on Infectious Diseases, Psychiatry and Mental health, Genetics, Cardiology and Cardiovascular Medicine and Nuclear Energy and Engineering, having authored 13 papers that have together received 1.9k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), Epilepsy research and treatment (3 papers), Genetic Associations and Epidemiology (2 papers) and Atrial Fibrillation Management and Outcomes (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (35 citations), Neurology (67 citations) and Statistics and Probability (47 citations). Vicky Collins has collaborated with scholars based in United Kingdom, Vietnam and Netherlands. Their work appears in journals such as The Lancet, Nature, Brain Communications, The Lancet Neurology and Lara D. Veeken.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.